Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354432 · ClinicalTrials.gov registry record · Phase 3
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00354432 is a Phase 3 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 120 participants.
The verdict
NCT00354432, a Phase 3 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer. It is not yet known whether soy protein/isoflavones are more effective than venlafaxine when given together or with a placebo in treating hot flashes. PURPOSE: This randomized phase III trial is studying soy protein/isoflavones and venlafaxine to compare how well they work when given together or with a placebo in treating hot flashes in patients receiving hormone therapy for prostate cancer.
Interventions
- DRUG Placebo Pill
- DIETARY_SUPPLEMENT Placebo Powder
- DRUG Venlafaxine
- DIETARY_SUPPLEMENT oral soy protein/isoflavones powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2007-02-01 |
| Est. Completion | 2010-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00354432
The ClinicalTrials.gov registry entry for NCT00354432 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Pill is the first listed.
NCT00354432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00354432 about?
NCT00354432 is a clinical study titled "Soy Protein/Effexor Hormone Therapy for Prostate Cancer". RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer. It is not yet known whether soy protein/isoflavones are more effective than venlafaxine when given together or with a placebo in treating hot flashes. PURPOSE: ...
What is the current status of trial NCT00354432?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2007-02-01. Estimated completion is 2010-08-01.
What interventions are being tested in trial NCT00354432?
The interventions under investigation include: Placebo Pill (DRUG), Placebo Powder (DIETARY_SUPPLEMENT), Venlafaxine (DRUG), oral soy protein/isoflavones powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00354432?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.